Global Amyotrophic Lateral Sclerosis (ALS) Market - 2025-2033
Overview
The global amyotrophic lateral sclerosis (ALS) market reached US$ 0.82 billion in 2024 and is expected to reach US$ 1.22 billion by 2033, growing at a CAGR of 5.1 % during the forecast period of 2025-2033.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that affects the motor neurons. These neurons control the body’s muscle movement and respiration. A person affected with ALS experiences progressive loss of motor function, muscle weakness, loss of movement, and later the ability to breathe. The causes of ALS are unknown, but research efforts have confirmed the role of genetics to be the main cause in certain cohorts.
The existing treatment modalities of ALS majorly focus on slowing down the disease progression and include drugs like Riluzole, Edaravone, Tofersen, etc. In addition to pharmacotherapy, multidisciplinary care, including physical therapy, respiratory support, and nutritional interventions, is crucial for extending survival and enhancing patient well-being.
Market Dynamics: Drivers & Restraints
Successful R&D Activities and New Drug Approvals
ALS is fatal, and only a handful of drugs are currently approved for slowing down the disease’s progression and improving the patient’s quality of life. In recent times, several drugs have received regulatory nod for marketing authorization in various regions across the globe.
For instance, in April 2023, the U.S. Food and Drug Administration (FDA) provided accelerated approval for a new drug called tofersen (QALSODY), for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. QALSODY is developed by Biogen Inc. is available in 100 mg/15mL injection and is the first drug to target the genes.
QALSODY received marketing authorization in the European Union (EU) in May 2024 and is the second drug after riluzole authorized for use in the EU for ALS.
Moreover, in September 2024, Eisai Co., Ltd. announced the marketing authorization approval in Japan for Rozebalamin (Mecobalamin) to treat patients with ALS. These recent drug approvals widen the treatment options for ALS patients and improve the overall treatment rate, driving the market growth.
Drug Discontinuation
The treatment options for ALS are very limited, with only a handful of drugs approved and available on the market. Any discrepancy in the supply chain of these drugs, or product discontinuation may impact the treatment adherence by patients and impact the overall market growth.
A notable example is the recent drug discontinuation by Mitsubishi Tanabe Pharma America, Inc. (MTPA). Mitsubishi Tanabe is commercializing EXSERVAN, which is a riluzole oral film formulation in the U.S. Market. However, in July 2024, the company decided to discontinue Exservan.
Moreover, MTPA also announced the discontinuation of intravenous RADICAVA (edaravone) in October 2024. The drug was first approved in 2017 by the U.S. FDA and will not be available to patients from April 2025. In addition, one of the novel drugs developed for ALS, i.e., RELYVRIO/ALBRIOZA by AMYLYX Pharmaceuticals, was also withdrawn from the market in 2024. These drug withdrawals can significantly hinder the treatment rate and the market supply chain.
Segment Analysis
The global amyotrophic lateral sclerosis (ALS) market is segmented based on disease type, treatment type, distribution channel, and region.
Treatment Type:
The riluzole segment in treatment type is expected to dominate the global amyotrophic lateral sclerosis (ALS) market with the highest market share
Riluzole was the first drug to be indicated for ALS, and its long-standing presence has earned it widespread clinical adoption and trust among healthcare professionals. It remains the most commonly prescribed treatment for ALS globally. This leadership is driven by its proven efficacy in extending patient survival and delaying the progression of the disease, especially in its earlier stages.
Riluzole functions by inhibiting the release of glutamate, a neurotransmitter that, in excessive amounts, is neurotoxic and contributes to the degeneration of motor neurons, a hallmark of ALS. By regulating this excitotoxicity, Riluzole helps reduce neuronal damage, thereby modestly prolonging life expectancy and delaying the need for invasive respiratory support in ALS patients. Although it is not curative and its benefits are limited to slowing progression rather than halting or reversing it, its role as a foundational treatment in ALS therapy remains strong.
Another key factor contributing to Riluzole's dominance is its global accessibility and the availability of generic formulations, which make it cost-effective and widely distributed in both developed and emerging markets. It is available in multiple forms, including tablets and oral suspensions, the latter catering to ALS patients who often develop difficulties with swallowing. These formulations have expanded their usability across different stages of disease severity.
Despite the advent of newer treatments such as Edaravone, Tofersen, and experimental gene therapies, Riluzole continues to play a vital role in ALS treatment protocols. It is frequently used in combination with other drugs to create a multi-pronged approach to disease management. These factors have solidified the segment's position in the global amyotrophic lateral sclerosis (ALS) market.
Geographical Analysis
North America is expected to hold a significant position in the global amyotrophic lateral sclerosis (ALS) market with the highest market share
North America dominates the ALS market due to its advanced healthcare infrastructure and higher prevalence of the condition. For instance, as per the epidemiological study published in the Taylor and Francis Journal, the total prevalence cases of ALS in the U.S. in 2022 was 32,893. By 2030 these cases are expected to reach 36,308 with a rise of approximately 10%.
North America, particularly the United States and Canada, possesses well-developed healthcare systems with robust infrastructure, including hospitals, specialty clinics, research institutions, and rehabilitation centers. This infrastructure facilitates the timely diagnosis, treatment, and management of ALS patients. Moreover, advanced mobility aids, communication devices, respiratory support systems, and other assistive technologies are readily available in the region.
In addition, any novel drug discovered for ALS first gets launched in the U.S. market due to higher demand. Hence, the patient population gets first access to these interventions. Moreover, manufacturers tend to generate most of their revenue from the region due to higher costs and higher demand. Thus, the above factors are consolidating the region's position as a dominant force in the global amyotrophic lateral sclerosis (ALS) market.
Competitive Landscape
The major global players in the amyotrophic lateral sclerosis (ALS) market include BIOGEN, Sanofi, Otsuka Holdings Co., Ltd., Mitsubishi Tanabe Pharma, EDW Pharma, Inc., BrainStorm Cell Therapeutics, Eisai Co., Ltd., Rappta Therapeutics, AB Science, and CorestemChemon Inc., among others.
Key Developments
Target Audience 2024
The global amyotrophic lateral sclerosis (ALS) market reached US$ 0.82 billion in 2024 and is expected to reach US$ 1.22 billion by 2033, growing at a CAGR of 5.1 % during the forecast period of 2025-2033.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder that affects the motor neurons. These neurons control the body’s muscle movement and respiration. A person affected with ALS experiences progressive loss of motor function, muscle weakness, loss of movement, and later the ability to breathe. The causes of ALS are unknown, but research efforts have confirmed the role of genetics to be the main cause in certain cohorts.
The existing treatment modalities of ALS majorly focus on slowing down the disease progression and include drugs like Riluzole, Edaravone, Tofersen, etc. In addition to pharmacotherapy, multidisciplinary care, including physical therapy, respiratory support, and nutritional interventions, is crucial for extending survival and enhancing patient well-being.
Market Dynamics: Drivers & Restraints
Successful R&D Activities and New Drug Approvals
ALS is fatal, and only a handful of drugs are currently approved for slowing down the disease’s progression and improving the patient’s quality of life. In recent times, several drugs have received regulatory nod for marketing authorization in various regions across the globe.
For instance, in April 2023, the U.S. Food and Drug Administration (FDA) provided accelerated approval for a new drug called tofersen (QALSODY), for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. QALSODY is developed by Biogen Inc. is available in 100 mg/15mL injection and is the first drug to target the genes.
QALSODY received marketing authorization in the European Union (EU) in May 2024 and is the second drug after riluzole authorized for use in the EU for ALS.
Moreover, in September 2024, Eisai Co., Ltd. announced the marketing authorization approval in Japan for Rozebalamin (Mecobalamin) to treat patients with ALS. These recent drug approvals widen the treatment options for ALS patients and improve the overall treatment rate, driving the market growth.
Drug Discontinuation
The treatment options for ALS are very limited, with only a handful of drugs approved and available on the market. Any discrepancy in the supply chain of these drugs, or product discontinuation may impact the treatment adherence by patients and impact the overall market growth.
A notable example is the recent drug discontinuation by Mitsubishi Tanabe Pharma America, Inc. (MTPA). Mitsubishi Tanabe is commercializing EXSERVAN, which is a riluzole oral film formulation in the U.S. Market. However, in July 2024, the company decided to discontinue Exservan.
Moreover, MTPA also announced the discontinuation of intravenous RADICAVA (edaravone) in October 2024. The drug was first approved in 2017 by the U.S. FDA and will not be available to patients from April 2025. In addition, one of the novel drugs developed for ALS, i.e., RELYVRIO/ALBRIOZA by AMYLYX Pharmaceuticals, was also withdrawn from the market in 2024. These drug withdrawals can significantly hinder the treatment rate and the market supply chain.
Segment Analysis
The global amyotrophic lateral sclerosis (ALS) market is segmented based on disease type, treatment type, distribution channel, and region.
Treatment Type:
The riluzole segment in treatment type is expected to dominate the global amyotrophic lateral sclerosis (ALS) market with the highest market share
Riluzole was the first drug to be indicated for ALS, and its long-standing presence has earned it widespread clinical adoption and trust among healthcare professionals. It remains the most commonly prescribed treatment for ALS globally. This leadership is driven by its proven efficacy in extending patient survival and delaying the progression of the disease, especially in its earlier stages.
Riluzole functions by inhibiting the release of glutamate, a neurotransmitter that, in excessive amounts, is neurotoxic and contributes to the degeneration of motor neurons, a hallmark of ALS. By regulating this excitotoxicity, Riluzole helps reduce neuronal damage, thereby modestly prolonging life expectancy and delaying the need for invasive respiratory support in ALS patients. Although it is not curative and its benefits are limited to slowing progression rather than halting or reversing it, its role as a foundational treatment in ALS therapy remains strong.
Another key factor contributing to Riluzole's dominance is its global accessibility and the availability of generic formulations, which make it cost-effective and widely distributed in both developed and emerging markets. It is available in multiple forms, including tablets and oral suspensions, the latter catering to ALS patients who often develop difficulties with swallowing. These formulations have expanded their usability across different stages of disease severity.
Despite the advent of newer treatments such as Edaravone, Tofersen, and experimental gene therapies, Riluzole continues to play a vital role in ALS treatment protocols. It is frequently used in combination with other drugs to create a multi-pronged approach to disease management. These factors have solidified the segment's position in the global amyotrophic lateral sclerosis (ALS) market.
Geographical Analysis
North America is expected to hold a significant position in the global amyotrophic lateral sclerosis (ALS) market with the highest market share
North America dominates the ALS market due to its advanced healthcare infrastructure and higher prevalence of the condition. For instance, as per the epidemiological study published in the Taylor and Francis Journal, the total prevalence cases of ALS in the U.S. in 2022 was 32,893. By 2030 these cases are expected to reach 36,308 with a rise of approximately 10%.
North America, particularly the United States and Canada, possesses well-developed healthcare systems with robust infrastructure, including hospitals, specialty clinics, research institutions, and rehabilitation centers. This infrastructure facilitates the timely diagnosis, treatment, and management of ALS patients. Moreover, advanced mobility aids, communication devices, respiratory support systems, and other assistive technologies are readily available in the region.
In addition, any novel drug discovered for ALS first gets launched in the U.S. market due to higher demand. Hence, the patient population gets first access to these interventions. Moreover, manufacturers tend to generate most of their revenue from the region due to higher costs and higher demand. Thus, the above factors are consolidating the region's position as a dominant force in the global amyotrophic lateral sclerosis (ALS) market.
Competitive Landscape
The major global players in the amyotrophic lateral sclerosis (ALS) market include BIOGEN, Sanofi, Otsuka Holdings Co., Ltd., Mitsubishi Tanabe Pharma, EDW Pharma, Inc., BrainStorm Cell Therapeutics, Eisai Co., Ltd., Rappta Therapeutics, AB Science, and CorestemChemon Inc., among others.
Key Developments
- In September 2024, Eisai Co., Ltd. announced the marketing authorization approval in Japan for Rozebalamin (Mecobalamin) to treat patients with ALS.
- In August 2023, the U.S. Food and Drug Administration (FDA) provided accelerated approval for a new drug called tofersen (QALSODY) for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. QALSODY is developed by Biogen Inc. and is available in 100 mg/15mL injection and is the first drug to target the genes.
- Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
- Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
- Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
- Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
- Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
- Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
- Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
- Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
- Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
- Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
- Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
- Post-market Surveillance: Uses post-market data to enhance product safety and access.
- Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
Target Audience 2024
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Disease Type
2.4. Snippet by Treatment Type
2.5. Snippet by Distribution Channel
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Successful R&D Activities and New Drug Approvals
3.1.1.2. Advancements in Biotechnology & Gene Therapy
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Drug Discontinuation
3.1.2.2. High Treatment Costs
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Personalized Medicine and Biomarker Development
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with the largest-selling Brand
4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Regulatory and Reimbursement Landscape
4.4.1. North America
4.4.2. Europe
4.4.3. Asia Pacific
4.4.4. South America
4.4.5. Middle East & Africa
4.5. Porter’s Five Forces Analysis
4.6. Supply Chain Analysis
4.7. Patent Analysis
4.8. SWOT Analysis
4.9. Unmet Needs and Gaps
4.10. Recommended Strategies for Market Entry and Expansion
4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.12. Pricing Analysis and Price Dynamics
4.13. Key Opinion Leaders
5. AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET, BY DISEASE TYPE
5.1. Introduction
5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Disease Type
5.1.2. Market Attractiveness Index By Disease Type
5.2. Sporadic ALS*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Familial ALS (FALS)
6. AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET, BY TREATMENT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index By Treatment Type
6.2. Riluzole*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Edaravone
6.4. Sodium Phenylbutyrate and Taurursodiol
6.5. Tofersen
6.6. Dextromethorphan HBr and Quinidine Sulfate
6.7. Others
7. AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET, BY DISTRIBUTION CHANNEL
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
7.1.2. Market Attractiveness Index By Distribution Channel
7.2. Hospital Pharmacies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Retail Pharmacies
7.4. Online Pharmacies
8. AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. BIOGEN *
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Sanofi
10.3. Otsuka Holdings Co., Ltd.
10.4. Mitsubishi Tanabe Pharma
10.5. EDW Pharma, Inc.
10.6. BrainStorm Cell Therapeutics
10.7. Eisai Co., Ltd.
10.8. Rappta Therapeutics
10.9. AB Science
10.10. CorestemChemon Inc.
LIST NOT EXHAUSTIVE
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Disease Type
2.4. Snippet by Treatment Type
2.5. Snippet by Distribution Channel
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Successful R&D Activities and New Drug Approvals
3.1.1.2. Advancements in Biotechnology & Gene Therapy
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Drug Discontinuation
3.1.2.2. High Treatment Costs
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Personalized Medicine and Biomarker Development
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with the largest-selling Brand
4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Regulatory and Reimbursement Landscape
4.4.1. North America
4.4.2. Europe
4.4.3. Asia Pacific
4.4.4. South America
4.4.5. Middle East & Africa
4.5. Porter’s Five Forces Analysis
4.6. Supply Chain Analysis
4.7. Patent Analysis
4.8. SWOT Analysis
4.9. Unmet Needs and Gaps
4.10. Recommended Strategies for Market Entry and Expansion
4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.12. Pricing Analysis and Price Dynamics
4.13. Key Opinion Leaders
5. AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET, BY DISEASE TYPE
5.1. Introduction
5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Disease Type
5.1.2. Market Attractiveness Index By Disease Type
5.2. Sporadic ALS*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Familial ALS (FALS)
6. AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET, BY TREATMENT TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index By Treatment Type
6.2. Riluzole*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Edaravone
6.4. Sodium Phenylbutyrate and Taurursodiol
6.5. Tofersen
6.6. Dextromethorphan HBr and Quinidine Sulfate
6.7. Others
7. AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET, BY DISTRIBUTION CHANNEL
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
7.1.2. Market Attractiveness Index By Distribution Channel
7.2. Hospital Pharmacies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Retail Pharmacies
7.4. Online Pharmacies
8. AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. U.K.
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. Brazil
8.4.6.2. Argentina
8.4.6.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.6.1. China
8.5.6.2. India
8.5.6.3. Japan
8.5.6.4. South Korea
8.5.6.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. BIOGEN *
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Sanofi
10.3. Otsuka Holdings Co., Ltd.
10.4. Mitsubishi Tanabe Pharma
10.5. EDW Pharma, Inc.
10.6. BrainStorm Cell Therapeutics
10.7. Eisai Co., Ltd.
10.8. Rappta Therapeutics
10.9. AB Science
10.10. CorestemChemon Inc.
LIST NOT EXHAUSTIVE
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 7 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 9 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 11 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 14 North America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 15 North America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 16 North America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 South America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 18 South America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 19 South America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 South America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 22 Europe Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 23 Europe Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Europe Amyotrophic Lateral Sclerosis (ALS) Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 BIOGEN: Overview
Table 34 BIOGEN: Product Portfolio
Table 35 BIOGEN: Key Developments
Table 36 Sanofi: Overview
Table 37 Sanofi: Product Portfolio
Table 38 Sanofi: Key Developments
Table 39 Otsuka Holdings Co., Ltd.: Overview
Table 40 Otsuka Holdings Co., Ltd.: Product Portfolio
Table 41 Otsuka Holdings Co., Ltd.: Key Developments
Table 42 Mitsubishi Tanabe Pharma: Overview
Table 43 Mitsubishi Tanabe Pharma: Product Portfolio
Table 44 Mitsubishi Tanabe Pharma: Key Developments
Table 45 EDW Pharma, Inc.: Overview
Table 46 EDW Pharma, Inc.: Product Portfolio
Table 47 EDW Pharma, Inc.: Key Developments
Table 48 BrainStorm Cell Therapeutics: Overview
Table 49 BrainStorm Cell Therapeutics: Product Portfolio
Table 50 BrainStorm Cell Therapeutics: Key Developments
Table 51 Eisai Co., Ltd. : Overview
Table 52 Eisai Co., Ltd. : Product Portfolio
Table 53 Eisai Co., Ltd. : Key Developments
Table 54 Rappta Therapeutics : Overview
Table 55 Rappta Therapeutics : Product Portfolio
Table 56 Rappta Therapeutics : Key Developments
Table 57 AB Science: Overview
Table 58 AB Science: Product Portfolio
Table 59 AB Science: Key Developments
Table 60 CorestemChemon Inc.: Overview
Table 61 CorestemChemon Inc.: Product Portfolio
Table 62 CorestemChemon Inc.: Key Developments
Table 1 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 7 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 9 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 11 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 14 North America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 15 North America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 16 North America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 South America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 18 South America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 19 South America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 South America Amyotrophic Lateral Sclerosis (ALS) Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Europe Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 22 Europe Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 23 Europe Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Europe Amyotrophic Lateral Sclerosis (ALS) Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 26 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 27 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 28 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Value, By Treatment Type, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 BIOGEN: Overview
Table 34 BIOGEN: Product Portfolio
Table 35 BIOGEN: Key Developments
Table 36 Sanofi: Overview
Table 37 Sanofi: Product Portfolio
Table 38 Sanofi: Key Developments
Table 39 Otsuka Holdings Co., Ltd.: Overview
Table 40 Otsuka Holdings Co., Ltd.: Product Portfolio
Table 41 Otsuka Holdings Co., Ltd.: Key Developments
Table 42 Mitsubishi Tanabe Pharma: Overview
Table 43 Mitsubishi Tanabe Pharma: Product Portfolio
Table 44 Mitsubishi Tanabe Pharma: Key Developments
Table 45 EDW Pharma, Inc.: Overview
Table 46 EDW Pharma, Inc.: Product Portfolio
Table 47 EDW Pharma, Inc.: Key Developments
Table 48 BrainStorm Cell Therapeutics: Overview
Table 49 BrainStorm Cell Therapeutics: Product Portfolio
Table 50 BrainStorm Cell Therapeutics: Key Developments
Table 51 Eisai Co., Ltd. : Overview
Table 52 Eisai Co., Ltd. : Product Portfolio
Table 53 Eisai Co., Ltd. : Key Developments
Table 54 Rappta Therapeutics : Overview
Table 55 Rappta Therapeutics : Product Portfolio
Table 56 Rappta Therapeutics : Key Developments
Table 57 AB Science: Overview
Table 58 AB Science: Product Portfolio
Table 59 AB Science: Key Developments
Table 60 CorestemChemon Inc.: Overview
Table 61 CorestemChemon Inc.: Product Portfolio
Table 62 CorestemChemon Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Disease Type, 2024 & 2033 (%)
Figure 3 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 4 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Amyotrophic Lateral Sclerosis (ALS) Market Y-o-Y Growth, By Disease Type, 2023-2033 (%)
Figure 7 Sporadic ALS Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 8 Familial ALS (FALS) Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 9 Global Amyotrophic Lateral Sclerosis (ALS) Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)
Figure 10 Riluzole Treatment Type in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 11 Edaravone Treatment Type in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 12 Sodium Phenylbutyrate and Taurursodiol Treatment Type in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 13 Tofersen Treatment Type in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 14 Dextromethorphan HBr and Quinidine Sulfate Treatment Type in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 15 Others Treatment Type in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Amyotrophic Lateral Sclerosis (ALS) Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 17 Hospital Pharmacies Distribution Channel in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 18 Retail Pharmacies Distribution Channel in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 19 Online Pharmacies Distribution Channel in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Amyotrophic Lateral Sclerosis (ALS) Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 21 North America Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 22 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Disease Type, 2024 & 2033 (%)
Figure 23 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 24 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 25 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, 2024 & 2033 (%)
Figure 26 South America Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 27 South America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Disease Type, 2024 & 2033 (%)
Figure 28 South America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 29 South America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 30 South America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Disease Type, 2024 & 2033 (%)
Figure 33 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 34 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 35 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, 2024 & 2033 (%)
Figure 36 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 37 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Disease Type, 2024 & 2033 (%)
Figure 38 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 39 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 40 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, 2024 & 2033 (%)
Figure 41 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 42 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Disease Type, 2024 & 2033 (%)
Figure 43 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 44 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 45 BIOGEN: Financials
Figure 46 Sanofi: Financials
Figure 47 Otsuka Holdings Co., Ltd.: Financials
Figure 48 Mitsubishi Tanabe Pharma: Financials
Figure 49 EDW Pharma, Inc.: Financials
Figure 50 BrainStorm Cell Therapeutics: Financials
Figure 51 Eisai Co., Ltd. : Financials
Figure 52 Rappta Therapeutics : Financials
Figure 53 AB Science: Financials
Figure 54 CorestemChemon Inc.: Financials
Figure 1 Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Disease Type, 2024 & 2033 (%)
Figure 3 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 4 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Amyotrophic Lateral Sclerosis (ALS) Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Amyotrophic Lateral Sclerosis (ALS) Market Y-o-Y Growth, By Disease Type, 2023-2033 (%)
Figure 7 Sporadic ALS Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 8 Familial ALS (FALS) Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 9 Global Amyotrophic Lateral Sclerosis (ALS) Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)
Figure 10 Riluzole Treatment Type in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 11 Edaravone Treatment Type in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 12 Sodium Phenylbutyrate and Taurursodiol Treatment Type in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 13 Tofersen Treatment Type in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 14 Dextromethorphan HBr and Quinidine Sulfate Treatment Type in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 15 Others Treatment Type in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 16 Global Amyotrophic Lateral Sclerosis (ALS) Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 17 Hospital Pharmacies Distribution Channel in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 18 Retail Pharmacies Distribution Channel in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 19 Online Pharmacies Distribution Channel in Global Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 20 Global Amyotrophic Lateral Sclerosis (ALS) Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 21 North America Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 22 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Disease Type, 2024 & 2033 (%)
Figure 23 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 24 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 25 North America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, 2024 & 2033 (%)
Figure 26 South America Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 27 South America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Disease Type, 2024 & 2033 (%)
Figure 28 South America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 29 South America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 30 South America Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, 2024 & 2033 (%)
Figure 31 Europe Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 32 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Disease Type, 2024 & 2033 (%)
Figure 33 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 34 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 35 Europe Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, 2024 & 2033 (%)
Figure 36 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 37 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Disease Type, 2024 & 2033 (%)
Figure 38 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 39 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 40 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Market Share, By Country, 2024 & 2033 (%)
Figure 41 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Value, 2022-2033 (US$ Billion)
Figure 42 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Disease Type, 2024 & 2033 (%)
Figure 43 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Treatment Type, 2024 & 2033 (%)
Figure 44 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 45 BIOGEN: Financials
Figure 46 Sanofi: Financials
Figure 47 Otsuka Holdings Co., Ltd.: Financials
Figure 48 Mitsubishi Tanabe Pharma: Financials
Figure 49 EDW Pharma, Inc.: Financials
Figure 50 BrainStorm Cell Therapeutics: Financials
Figure 51 Eisai Co., Ltd. : Financials
Figure 52 Rappta Therapeutics : Financials
Figure 53 AB Science: Financials
Figure 54 CorestemChemon Inc.: Financials
